Literature DB >> 17128152

[MUC1 (EMA): A key molecule of carcinogenesis?].

Xavier Leroy1, Marie-Pierre Buisine, Emmanuelle Leteurtre, Sebastien Aubert, David Buob, Nicole Porchet, Marie-Christine Copin.   

Abstract

MUC1 is a large trans-membrane highly glycosylated mucin which is expressed at the apical pole of normal cells in glandular epithelia. MUC1 is implicated in many physiological mechanisms such as adhesion, development and differentiation. Also, MUC1 is frequently deregulated and over-expressed with a membrane circumferential and/or cytoplasmic expression. The intracellular tail of MUC1 is phosphorylated and can interact with many signalling proteins and transcriptional factors. Indeed, MUC1 can interact with B-catenin competitively for E-cadherin, thus destabilizing intercellular junctions and favouring metastatic dissemination. In carcinomas, the overexpression and membrane delocalization of MUC1 is associated with a worse prognosis and a shorter survival in breast, colon, kidney, prostate or gastro-intestinal cancers. MUC1 appears to be a novel therapeutic target for immunotherapy or anti-tumour vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17128152     DOI: 10.1016/s0242-6498(06)70718-0

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  6 in total

1.  Exploring the structural constraints at cleavage site of mucin 1 isoform through molecular dynamics simulation.

Authors:  J Lesitha Jeeva Kumari; C Sudandiradoss
Journal:  Eur Biophys J       Date:  2015-04-11       Impact factor: 1.733

2.  LINC00173 promotes Wilms' tumor progression through MGAT1-mediated MUC3A N-glycosylation.

Authors:  Qingliang Zhu; Deming Zhan; Yongguo Yang; Yankun Chong; Haoliang Xue; Peng Zhu
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 3.  Early detection of breast cancer: new biomarker tests on the horizon?

Authors:  Aparna C Jotwani; Julie R Gralow
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

4.  Evaluation of peptide designing strategy against subunit reassociation in mucin 1: A steered molecular dynamics approach.

Authors:  J Lesitha Jeeva Kumari; R Jesu Jaya Sudan; C Sudandiradoss
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

5.  Clinical effect of MUC1 and its relevance to BRAF V600E mutation in papillary thyroid carcinoma: a case-control study.

Authors:  Quan Li; Wen-Xu Jin; Yi-Xiang Jin; Zhou-Ci Zheng; Xiao-Fen Zhou; Qing-Xuan Wang; Dan-Rong Ye; Yi-Han Sun; Xiao-Hua Zhang; Ou-Chen Wang; En-Dong Chen; Ye-Feng Cai
Journal:  Cancer Manag Res       Date:  2018-05-29       Impact factor: 3.989

Review 6.  Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?

Authors:  Henning M Schramm
Journal:  J Cancer       Date:  2014-01-15       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.